Drug intelligence / Profile preview

Tungsten

Development stage: Preclinical
Modality: DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
Administration: Oral

Overview

Tungsten, likely in the form of a tungsten compound such as sodium tungstate, functions as a xanthine oxidase (XO) inhibitor. In preclinical studies, it has been shown to prevent the development of atherosclerosis and endothelial dysfunction in hyperlipidemic ApoE knockout mice by lowering plasma XO activity and attenuating vascular superoxide anion formation. Xanthine oxidase is an enzyme that generates reactive oxygen species (ROS), which are implicated in the progression of atherosclerosis. By inhibiting XO, tungsten reduces oxidative stress, thereby mitigating vascular damage. [cite: PMID: 17023262]

Targets

XO (Xanthine Oxidoreductase)

Beyond the preview

Go deeper on Tungsten.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tungsten.

Explore the full profile